Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis.
暂无分享,去创建一个
F. Ciccia | R. Giacomelli | R. Grembiale | F. Perosa | P. Ruscitti | V. Liakouli | P. Cipriani | F. Cantatore | L. Navarini | A. Corrado | E. Favoino | M. Vomero | Adriana Sisto
[1] E. Kazerooni,et al. Risk factors for lung function decline in systemic sclerosis-associated interstitial lung disease in a large single-center cohort. , 2022, Rheumatology.
[2] C. Foti,et al. Circulating Irisin Levels in Patients with Chronic Plaque Psoriasis , 2022, Biomolecules.
[3] G. Valesini,et al. Novel biomarker for pulmonary vascular disease in systemic sclerosis patients. , 2021, Clinical and experimental rheumatology.
[4] C. Denton,et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis , 2020, Arthritis & rheumatology.
[5] M. Malaise,et al. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature , 2019, Rheumatology.
[6] F. Perosa,et al. CD20-Mimotope Peptides: A Model to Define the Molecular Basis of Epitope Spreading , 2019, International journal of molecular sciences.
[7] G. Valentini,et al. Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association , 2018, PloS one.
[8] C. Denton,et al. SYSTEMIC SCLEROSIS , 2008 .
[9] G. Valentini,et al. Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease , 2016, Medicine.
[10] S. Harari,et al. Cellular interactions in the pathogenesis of interstitial lung diseases , 2015, European Respiratory Review.
[11] Sindhu R Johnson,et al. Lung Function and Survival in Systemic Sclerosis Interstitial Lung Disease , 2014, The Journal of Rheumatology.
[12] X. Corbella,et al. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. , 2014, Seminars in arthritis and rheumatism.
[13] H. Collard,et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. , 2014, Chest.
[14] A. Wells,et al. Prediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis , 2014, Arthritis & rheumatology.
[15] Oliver Distler,et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. , 2013, Arthritis and rheumatism.
[16] F. Dammacco,et al. Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis , 2013, Arthritis Research & Therapy.
[17] G. Valentini,et al. Autoantibodies Recognizing the Amino Terminal 1-17 Segment of CENP-A Display Unique Specificities in Systemic Sclerosis , 2013, PloS one.
[18] M. Bernaudin,et al. Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study. , 2013, The American journal of pathology.
[19] G. Valentini,et al. Peripheral T cells from patients with early systemic sclerosis kill autologous fibroblasts in co-culture: is T-cell response aimed to play a protective role? , 2010, Rheumatology.
[20] E. Feierl,et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.
[21] M. Humbert,et al. Antifibroblast antibodies from systemic sclerosis patients bind to α-enolase and are associated with interstitial lung disease , 2009, Annals of the rheumatic diseases.
[22] V. De Pinto,et al. Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes1 , 2009, The Journal of Immunology.
[23] R. Rezzonico,et al. Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. , 2008, Arthritis and rheumatism.
[24] M. Gershwin,et al. The immunobiology of systemic sclerosis. , 2008, Seminars in arthritis and rheumatism.
[25] M. Humbert,et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.
[26] S. Kaveri,et al. Identification of target antigens of antiendothelial cell antibodies in healthy individuals: A proteomic approach , 2008, Proteomics.
[27] J. Dayer,et al. Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts. , 2007, Rheumatology.
[28] S. Svegliati,et al. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. , 2007, Autoimmunity reviews.
[29] David Abraham,et al. Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.
[30] U. Müller-Ladner,et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.
[31] A. Gabrielli,et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.
[32] G. Valentini,et al. Peripheral T lymphocytes from patients with early systemic sclerosis co‐cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin , 2006, Clinical and experimental immunology.
[33] F. Dammacco,et al. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. , 2006, Blood.
[34] D. Milewicz,et al. Autoantibodies to Fibrillin-1 Activate Normal Human Fibroblasts in Culture through the TGF-β Pathway to Recapitulate the “Scleroderma Phenotype”1 , 2005, The Journal of Immunology.
[35] J. Baik,et al. Human α-enolase from endothelial cells as a target antigen of anti–endothelial cell antibody in Behçet's disease , 2003 .
[36] N. Ronda,et al. Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. , 2002, Arthritis and rheumatism.
[37] A. Gabrielli,et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. , 2002, Arthritis and rheumatism.
[38] François Tron,et al. Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. , 2002, Arthritis and rheumatism.
[39] S. Jimenez,et al. Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis1 , 2002, The Journal of Immunology.
[40] Orth,et al. Identification and characterization of autoantibodies against catalase and α‐enolase in patients with primary sclerosing cholangitis , 1998 .
[41] Zhao,et al. Catalase and α‐enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD) , 1998 .
[42] T. Medsger,et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.